Ultime notizie per Gelesis Hldgs (OTC:GLSHQ) Azioni

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

GELESIS HOLDINGS INC by Gelesis Holdings, Inc.

Gelesis Holdings Inc

Goldman Sachs identified 20 stocks with high short interest that could be primed for a short squeeze, particularly if upcoming earnings reports exceed expectations, <a href="https://www.benzinga.com/short-interest/most-shorted">providing opportunities for traders. </a>
In a note shared this week, analyst John Marshall and his team saw the potential for substantial upside for this group of stocks if the current trend of short-covering continues.
<h3 class="wp-block-heading">What Is A Short Squeeze?</h3>
A short squeeze happens when a stock with high short interest sees a rapid price surge, forcing short sellers to buy back shares to cover their positions. This buying frenzy often propels the stock price even higher. 
Short sellers bet that the price of a stock will fall, borrowing shares to sell them at the current price with the intent of repurchasing them at a lower price. 
When a stock rises instead, short sellers scramble to cover their positions, accelerating the stock&#8217;s upward momentum.
Short squeezes typically occur when heavily shorted stocks see unexpected positive news or earnings results, triggering forced buying.
<h3 class="wp-block-heading">Relief Rallies On Earnings</h3>
Goldman analysts also highlighted that heavily shorted stocks tend to be more prone to &#8220;relief rallies&#8221; around earnings. 
A relief rally occurs when stocks perform better than expected after earnings, alleviating bearish concerns and pushing share prices higher.
"We see greater than normal potential for relief rallies on earnings," said Marshall.
The Goldman Sachs team screened for 20 stocks with high short interest, liquid options, upcoming earnings, and a Buy rating from their equity research department.
Analysts at Goldman Sachs recommend to buy call options in order to bet on a potential short squeeze. 
Call options give investors the right, but not the obligation, to buy a stock at a specific price within a set timeframe. This strategy limits risk while allowing for participation in any significant price increases due to a short squeeze or positive earnings surprise.
Read also: <a href="https://www.benzinga.com/markets/24/10/41302909/18-stocks-to-buy-7-to-sell-this-earnings-season-goldman-sachs-calls-it-the-year-of-the-stock-picker">18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It &#8216;The Year Of The Stock Picker&#8217;</a>
<h3 class="wp-block-heading">Goldman Sachs Names 20 Stocks Primed For Short-Squeeze Rallies</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Earnings Date</th>
<th>Short Interest (% of Float)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chewy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)</td>
<td>Dec 4 (After Market Close)</td>
<td>10.7%</td>
</tr>
<tr>
<td>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>Oct 22 (AMC)</td>
<td>10.6%</td>
</tr>
<tr>
<td>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>Oct 31 (Before Market Open)</td>
<td>9.1%</td>
</tr>
<tr>
<td>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)</td>
<td>Nov 6 (AMC)</td>
<td>8.4%</td>
</tr>
<tr>
<td>Dick&#8217;s Sporting Goods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>)</td>
<td>Nov 19 (BMO)</td>
<td>7.6%</td>
</tr>
<tr>
<td>Best Buy Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)</td>
<td>Nov 19 (BMO)</td>
<td>7.1%</td>
</tr>
<tr>
<td>TKO Group Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>)</td>
<td>Nov 6 (AMC)</td>
<td>6.8%</td>
</tr>
<tr>
<td>Dollar Tree Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>)</td>
<td>Nov 27 (BMO)</td>
<td>5.8%</td>
</tr>
<tr>
<td>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>Oct 28 (BMO)</td>
<td>5.6%</td>
</tr>
<tr>
<td>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>)</td>
<td>Nov 5 (BMO)</td>
<td>5.5%</td>
</tr>
<tr>
<td>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)</td>
<td>Oct 31 (AMC)</td>
<td>5.3%</td>
</tr>
<tr>
<td>Expedia Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)</td>
<td>Nov 7 (AMC)</td>
<td>5.2%</td>
</tr>
<tr>
<td>Vertiv Holdings Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>)</td>
<td>Oct 23 (BMO)</td>
<td>5.2%</td>
</tr>
<tr>
<td>Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>)</td>
<td>Oct 29 (BMO)</td>
<td>4.9%</td>
</tr>
<tr>
<td>First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)</td>
<td>Oct 29 (AMC)</td>
<td>4.8%</td>
</tr>
<tr>
<td>MongoDB Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>)</td>
<td>Dec 3 (BMO)</td>
<td>4.7%</td>
</tr>
<tr>
<td>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</td>
<td>Nov 25 (AMC)</td>
<td>4.7%</td>
</tr>
<tr>
<td>Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>)</td>
<td>Oct 30 (BMO)</td>
<td>4.7%</td>
</tr>
<tr>
<td>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)</td>
<td>Nov 27 (AMC)</td>
<td>4.5%</td>
</tr>
<tr>
<td>CrowdStrike Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</td>
<td>Nov 26 (AMC)</td>
<td>4.4%</td>
</tr>
</tbody>
</table>
</figure>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41314387/most-widely-hated-bull-market-reaches-2-year-milestone-top-20-s-p-500-stocks-drivin">&#8216;Most Widely Hated&#8217; Bull Market Reaches 2-Year Milestone: Top 20 S&amp;P 500 Stocks Driving The Rally</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Equities

Large Cap

Mid Cap

Tech

AFRM

CHWY

CRWD

DELL

DKNG

DLTR

ENPH

EXPE

FSLR

GNRC

MRNA

SNOW

Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the financials sector.
<h3 class="wp-block-heading">Columbia Banking System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>)</h3>
<ul>
<li>Dividend Yield: 5.19%</li>
<li>JP Morgan analyst Steven Alexopoulos maintained a Neutral rating and cut the price target from $29 to $28 on Oct. 9. This analyst has an accuracy rate of 71%.</li>
<li>Raymond James analyst David Feaster maintained an Outperform rating and raised the price target from $26 to $28 on Oct. 2. This analyst has an accuracy rate of 68%</li>
<li>Recent News: Columbia Banking System, will release third quarter financial results on Thursday, Oct. 24, before market open.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101824&amp;t=be2bearmibe3na1">COLB news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18091917/image-161.png" alt="" class="wp-image-602713" style="width:695px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18091917/image-161.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18091917/image-161-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18091917/image-161-768x714.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Lincoln National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>)</h3>
<ul>
<li>Dividend Yield: 5.35%</li>
<li>Wells Fargo analyst Elyse Greenspan maintained an Equal-Weight rating and raised the price target from $28 to $29 on Oct. 10. This analyst has an accuracy rate of 68%.</li>
<li>TD Cowen analyst Daniel Bergman initiated coverage on the stock with a Hold rating with a price target of $34 on Oct. 9. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: Lincoln Financial is expected to report third quarter results on Oct. 31.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101824&amp;t=be2bearmibe3na1">latest LNC news.</a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="897" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18091924/image-162.png" alt="" class="wp-image-602714" style="width:691px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18091924/image-162.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18091924/image-162-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18091924/image-162-768x711.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
<h3 class="wp-block-heading">Main Street Capital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAIN#NYSE">MAIN</a>)</h3>
<ul>
<li>Dividend Yield: 7.86%</li>
<li>Morgan Stanley analyst Devin McDermott upgraded the stock from Underweight to Equal-Weight with a price target of $24 on Sept. 16. This analyst has an accuracy rate of 80%.</li>
<li>Barclays analyst Theresa Chen maintained an Equal-Weight rating and boosted the price target from $21 to $22 on Sept. 13. This analyst has an accuracy rate of 78%.</li>
<li>Recent News: On Oct. 15, Main Street reported preliminary estimate of third-quarter net investment income of 99 cents to $1.01 per share.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101824&amp;t=be2bearmibe3na1">trend in MAIN stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18092130/image-163.png" alt="" class="wp-image-602718" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18092130/image-163.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18092130/image-163-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18092130/image-163-768x705.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

Long Ideas

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

COLB

MAIN

Wall Street's Most Accurate Analysts Give Their Take On 3 Financials Stocks Delivering High-Dividend Yields

Citigroup analyst Andrew Schmidt downgrades Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) from Buy to Neutral and raises the price target from $72 to $90.

Downgrades

QTWO

Citigroup Downgrades Q2 Holdings to Neutral, Raises Price Target to $90

Truist Securities analyst Michael Ciarmoli maintains Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Hold and raises the price target from $270 to $304.

Truist Securities Maintains Hold on Curtiss-Wright, Raises Price Target to $304

On Friday, Gene Munster shared his insights on the ongoing AI market dynamics after key Nvidia supplier Taiwan Semiconductor Manufacturing Company Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) reported <a href="https://www.benzinga.com/news/earnings/24/10/41373163/nvidia-supplier-tsmc-reports-q3-revenue-earnings-beat-amid-rising-demand-for-ai-chips">impressive third-quarter performance</a>.
What Happened: Munster took to X and emphasized the importance of focusing on the broader AI landscape rather than short-term fluctuations. He pointed out that just two days prior, concerns arose among investors regarding a potential slowdown in the AI sector. This was sparked by ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) reducing its 2025 revenue forecast by approximately 18%. The prevailing theory suggested that a decline in demand for AI chip-making machines could indicate a slowdown in AI chip demand.
See Also: <a href="https://www.benzinga.com/news/24/09/40974511/iphone-15-pro-models-and-iphone-13-discontinued-by-apple-heres-why?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">iPhone 15 Pro Models and iPhone 13 Discontinued By Apple: Here&#8217;s Why</a>
However that was not the case. Munster highlighted that TSMC saw a 10% surge in its stock price after announcing a 6% increase in December revenue projections. TSMC also reported that its demand for CoWoS, a key AI technology, is outpacing its supply capabilities, despite efforts to double capacity annually. 
Munster stated, &#8220;I still believe we&#8217;re in front of a 2-4 year bull market driven by AI.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Today&#39;s another case study on why it&#39;s important to stay focused on the big AI picture versus the day-to-day noise. Two days ago, investors were concerned that the AI trade was starting to slow, based on <a href="https://twitter.com/search?q=%24ASML&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ASML</a> guiding 2025 revenue down by about 18%. The theory was that if the…
&mdash; Gene Munster (@munster_gene) <a href="https://twitter.com/munster_gene/status/1847010578017190048?ref_src=twsrc%5Etfw">October 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Munster&#8217;s comments come in the wake of TSMC&#8217;s impressive third-quarter results, which exceeded expectations due to robust demand for AI chips. TSMC&#8217;s revenue for the quarter reached NT$759.69 billion ($23.50 billion), marking a 39% year-over-year increase. This growth underscores the strong demand for advanced processor node technologies used in AI applications.
Additionally, Munster had previously addressed the market&#8217;s reaction to ASML&#8217;s guidance cut, describing it as an overreaction. As reported by <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41351475/after-asml-rocks-ai-hardware-names-gene-munster-explains-why-its-overreaction-ai-tr">Benzinga</a>, he noted that only a small portion of ASML&#8217;s revenue is directly tied to AI demand. Munster&#8217;s perspective suggests that the AI trade remains on track, with TSMC&#8217;s performance further supporting this outlook.
Price Action: As per<a href="https://pro.benzinga.com"> Benzinga Pro,</a> t the time of writing during the pre-market hours on Friday, Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was up by 0.70% while major semiconductor ETFs were also trading slightly upwards. iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) was up by 1% while Direxion Daily Semiconductor Bull 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXL#NYSE">SOXL</a>) was trading 3.20% higher. SP Funds S&amp;P World ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPWO#NYSE">SPWO</a>) which allows investments into TSM, was up by 1.54%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41356479/apple-spark-hope-for-americas-semiconductor-comeback-key-supplier-tsmc-reportedly-begins-producing-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Spark Hope For America&#8217;s Semiconductor Comeback: Key Supplier TSMC Reportedly Begins Producing Chip</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

General

ASML

SOXL

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

SPWO

Gene Munster Predicts 'Bull Market Driven By AI' Amid TSMC's Stellar Performance

Truist Securities analyst Michael Ciarmoli maintains Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) with a Hold and lowers the price target from $22 to $20.

ATRO

Truist Securities Maintains Hold on Astronics, Lowers Price Target to $20

American Express CEO Says U.S. Consumer Is Stable But Spending Is Lower Than Post-Pandemic Levels; CFO Says Impact Of Fed Rate Cuts On Our Net Interest Income Is Actually Quite Small; CFO Says The Fed Rate Cut Is Too Small And Too Early To See Any Impact In Terms Of Spend Patterns

Citigroup analyst Andrew Schmidt downgrades Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) from Buy to Neutral and lowers the price target from $118 to $110.

EEFT

Citigroup Downgrades Euronet Worldwide to Neutral, Lowers Price Target to $110

RBC Capital analyst Shagun Singh maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Outperform and raises the price target from $525 to $555.

ISRG

RBC Capital Maintains Outperform on Intuitive Surgical, Raises Price Target to $555

Truist Securities analyst Michael Ciarmoli maintains AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) with a Buy and lowers the price target from $10 to $8.

ASLE

Truist Securities Maintains Buy on AerSale, Lowers Price Target to $8

P&G CFO Says Co Saw Stock-Up Situation As A Quick Run Up Due To The Port Strike Which Didn't Really Have A Material Impact On This Quarter; The Stock-Up Situation Due To Port Strikes Was Very Short-Lived

Citigroup analyst Scott Gruber downgrades Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) from Buy to Neutral and lowers the price target from $25 to $19.

LBRT

Citigroup Downgrades Liberty Energy to Neutral, Lowers Price Target to $19

American Express CFO Says Impact Of Fed Rate Cuts On Our Net Interest Income Is Actually Quite Small

Ladenburg Thalmann analyst Glenn Mattson initiates coverage on Neonode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEON#NASDAQ">NEON</a>) with a Buy rating and announces Price Target of $16.5.

Initiation

NEON

Ladenburg Thalmann Initiates Coverage On Neonode with Buy Rating, Announces Price Target of $16.5

On Thursday,&nbsp;Aura Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41390774/multiple-clinical-complete-responses-demonstrated-following-single-low-dose-administration-of-bel-" rel="noreferrer noopener">bladder cancer (NMIBC)</a>.
To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility of local administration of bel-sar alone (n=5) and bel-sar with light activation (n=8).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40837403/aura-biosciences-touts-promising-data-from-eye-cancer-candidate" rel="noreferrer noopener">Aura Biosciences Touts Promising Data From Eye Cancer Candidate</a>.
The secondary endpoints are to evaluate biological activity and immune-mediated changes in the tumor microenvironment (TME).
In patients receiving bel-sar with light activation (n=8), 4 out of 5 patients with low-grade disease demonstrated a clinically complete response with no tumor cells remaining on histopathological evaluation.
Two out of 3 patients with high-grade disease demonstrated visual tumor shrinkage observed on cystoscopy.
The data in these eight patients receiving bel-sar with light activation showed clinical activity detectable as soon as seven days after a single low dose of bel-sar with light activation.
&#8220;A potentially differentiating aspect of this novel treatment is the rapid tumor response accompanied by an immune-oncology effect such as a marked CD8+ T-cell infiltration observed in just a matter of days with a single low dose. We believe this could have the potential to translate into a durable response. In parallel with expanding the ongoing Phase 1 trial, we are preparing for a Phase 2 trial to further evaluate bel-sar&#8217;s clinical activity and durability of response,&#8221; said Sabine Brookman-May, Senior Vice President, Therapeutic Area Head Urologic Oncology of Aura Biosciences.
In the safety analysis as of Sept. 9, data cut-off date (n=12), bel-sar was well-tolerated, with less than 10% of patients reporting Grade 1 and no Grade 2 or higher drug-related adverse events reported.
No serious adverse events have been reported.
Price Action: AURA stock traded 18.85% higher at $12.23 during after-hours trading on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo" target="_blank" rel="noreferrer noopener">Pharmacy Retailer CVS Health Backs Away From Annual Forecast, Names New CEO</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

AURA

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease

<ul>
<li>NVDA</li>
<li>NFLX</li>
<li>TSLA</li>
<li>AAPL</li>
<li>WAY</li>
<li>QQQ</li>
<li>MADE</li>
<li>AI</li>
<li>TSM</li>
<li>GOLD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

MADE

NFLX

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of October 18, 2024 (Via Swaggy Stocks)

Joe Rogan recently discussed how people are starting to think differently about capitalism, money and yes, one of his favorite topics – <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a>. In a <a href="https://www.youtube.com/watch?v=ws2ZsG3NNQc">conversation</a> with musician Jelly Roll, Rogan talked about how things are changing in both the entertainment world and the way people feel about capitalism. He said both areas have seen a lot of changes recently.
Don't Miss:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> 7-9% target yield with monthly dividends would you invest in it?</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
&#8220;Everybody&#8217;s worried about like this collapse of society because people, they give up on
capitalism. They tune in and drop out,&#8221; he started before saying, &#8220;I don&#8217;t think we should be worried about that. I don&#8217;t think that&#8217;s real.&#8221;&nbsp;
He believes that while some people might want to &#8220;drop out&#8221; of the system, it won't affect most people. He thinks those people are just the type who would probably reject the system no matter what.
Trending: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
Rogan added that some people will always want to drop out and avoid responsibility. If given an excuse, they will take it, but that's just their personality. He believes this type of person doesn't represent most people and that most people could benefit from the system, especially if they don&#8217;t have major mental health issues.
Although Rogan and Roll talked a lot about psychedelics in this episode, what&#8217;s more interesting is what Rogan discussed in a different episode with Michael Malice. In it, they talked about how psychedelics, like <a href="https://www.benzinga.com/markets/cannabis/24/09/40858292/magic-mushrooms-boosted-humanitys-evolutionary-success-new-study-says-did-psilocybin-make-early-">magic mushrooms</a>, could change the corporate world.&nbsp;
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
Yes, Rogan said that if these drugs became legal and business leaders started using them, <a href="https://www.benzinga.com/personal-finance/24/08/40133472/joe-rogan-tells-ceos-life-is-short-youre-wasting-all-your-time-trying-to-squeeze-as-much-money-a">they might start to care more about people</a> and less about making as much money as possible. He said this is a &#8220;psychedelic capitalist perspective,&#8221; in which maximizing profits is equated with doing the right thing and not hurting anyone.
On a similar note, Rogan laughed and added that this might even make it &#8220;much harder to get a good burger&#8221; since fast-food workers might quit their jobs after taking psychedelics and seeing things differently.
Trending: A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a>
In 2017, he compared this way of thinking to former President Donald Trump, saying Trump is like someone who believes &#8220;greed is good.&#8221; Rogan warned that this thinking is &#8220;a dangerous ideology&#8221; for society, saying, "I mean, our president is essentially the greed-is-good guy. I mean, that is who he is that's what he's done. He's pursued wealth at all cost."
Rogan&#8217;s ideas aren't without controversy. Even though he often talks <a href="https://www.benzinga.com/personal-finance/24/09/40909092/joe-rogan-says-education-addiction-recovery-and-homelessness-should-be-funded-more-its-a-good-id">against corporate greed</a>, he is friends with some of the world&#8217;s richest and most powerful people. He called <a href="https://www.benzinga.com/news/24/05/38978082/joe-rogan-says-elon-musk-is-his-favorite-billionaire-i-will-buy-teslas-as-long-as-they-sell-them-jus">Elon Musk his &#8220;favorite billionaire&#8221;</a> and said he&#8217;d keep buying Tesla cars to support him. Some have referred to Rogan as hypocritical because of this, particularly considering that his podcast is among the most popular.
Read Next:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>

Startups

'I Don't Think We Should Be Worried About That,' Says Joe Rogan About People Giving Up On Capitalism – 'I Don't Think That's Real'

Lake Street analyst Jacob Stephan downgrades Zuora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZUO#NYSE">ZUO</a>) from Buy to Hold and announces $10 price target.

Lake Street Downgrades Zuora to Hold, Announces $10 Price Target

Morgan Stanley analyst Bob Huang maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Overweight and raises the price target from $300 to $310.

Morgan Stanley Maintains Overweight on Progressive, Raises Price Target to $310

Lake Street analyst Ben Klieve downgrades MGP Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) from Buy to Hold and announces $75 price target.

MGPI

Lake Street Downgrades MGP Ingredients to Hold, Announces $75 Price Target

Biotech bankruptcies hit a record despite sector's recovery

ATHXQ

BIOCQ

CFRXQ

GLSHQ

HGENQ

IMPLQ

INFIQ

MEIP

ONCSQ

PRED

SRNEQ

THER

Gelesis Hldgs

Comments

Gelesis Hldgs

Notizie

Ultime notizie per Gelesis Hldgs (OTC:GLSHQ) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO